Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Tuscaloosa Research & Education Advancement Corporation |
---|---|
Information provided by: | Tuscaloosa Research & Education Advancement Corporation |
ClinicalTrials.gov Identifier: | NCT00203385 |
The primary objective is to evaluate the long-term efficacy of divalproex sodium (Depakote) in the continuation treatment of PTSD.
Condition | Intervention | Phase |
---|---|---|
PTSD |
Drug: Divalproex sodium |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study |
Official Title: | Maintenance Phase Treatment With Divalproex for Post Traumatic Stress Disorder |
Estimated Enrollment: | 30 |
Study Start Date: | May 2003 |
Study Completion Date: | March 2005 |
Patients who have participated in the 8-week randomized, double-blind, placebo-controlled treatment trial of divalproex for PTSD and have signed informed consent will be enrolled in a 24-week open-label divalproex continuation phase trial. Patients’ symptoms, side effects and compliance will be assessed every two weeks for 4 weeks, then every 4 weeks, thereafter, up to 24-weeks. Based on symptomology and occurrence of side effects, the investigator will titrate the medication in 500 mg (one tablet) increments every four days, as tolerated, until a maximum therapeutic benefit is achieved, not to exceed 3000 mg/day. The dosing is twice daily, with the higher dose at bedtime. Compliance will be assessed by monthly pill count and valproic acid levels at the week(s) 4, 12 and 24. Patients are given supportive clinical management during the clinic visits. An investigator is available by telephone 24 hrs a day in case of emergency. Patients may be seen more often if needed. Efficacy will be measured by the structured rating scales for depression, global function and assessment and PTSD. Results of this study will be used to evaluate the long-term efficacy of divalproex in the maintenance treatment of PTSD.
Ages Eligible for Study: | 19 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Alabama | |
Tuscaloosa Research & Education Advancement Corporation | |
Tuscaloosa, Alabama, United States, 35404 |
Principal Investigator: | Lori L Davis, MD | Tuscaloosa VA Medical Center |
Study ID Numbers: | TREAC Maintenance DVX PTSD, TREAC Maintenance DVX PTSD |
Study First Received: | September 12, 2005 |
Last Updated: | March 16, 2007 |
ClinicalTrials.gov Identifier: | NCT00203385 History of Changes |
Health Authority: | United States: Food and Drug Administration |
divalproex sodium, depakote, ptsd, long-term ptsd treatments |
Neurotransmitter Agents Tranquilizing Agents Anxiety Disorders Mental Disorders Psychotropic Drugs Central Nervous System Depressants |
Stress Disorders, Post-Traumatic Stress Antimanic Agents Valproic Acid Anticonvulsants Stress Disorders, Traumatic |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Enzyme Inhibitors Antimanic Agents Valproic Acid |
Stress Disorders, Traumatic Pharmacologic Actions Anxiety Disorders Mental Disorders Therapeutic Uses GABA Agents Stress Disorders, Post-Traumatic Central Nervous System Agents Anticonvulsants |